Bridging the Frontiers: The Rudensky Symposium and the Future of Immunotherapy on October 31, 2026 Posted by
Navigating the Frontiers of Medicine: A Comprehensive Review of the Week’s Clinical Breakthroughs on October 31, 2026 Posted by
The Silent Crisis: Why Stroke Rates Are Skyrocketing Among Young Adults on October 31, 2026 Posted by
Beyond the Stigma: Understanding the Evolution and Impact of National Recovery Month 2026 on October 31, 2026 Posted by
Legislative Momentum: New Bipartisan Efforts to Bolster the American Addiction Recovery Landscape on October 31, 2026 Posted by
Next is Now: CRI Annual Gala Unites Science and Humanity to Transform the Future of Immunotherapy on October 31, 2026 Posted by
Breaking the Chain: How a Newly Discovered "Docking Point" Could Neutralize Colon Cancer-Promoting Bacteria on October 31, 2026 Posted by
Bridging the Frontiers: The Rudensky Symposium and the Future of Immunotherapy on October 31, 2026 Posted by
Navigating the Frontiers of Medicine: A Comprehensive Review of the Week’s Clinical Breakthroughs on October 31, 2026 Posted by
The Silent Crisis: Why Stroke Rates Are Skyrocketing Among Young Adults on October 31, 2026 Posted by
Beyond the Stigma: Understanding the Evolution and Impact of National Recovery Month 2026 on October 31, 2026 Posted by
Posted in Digital Health Tools Biotech Markets in Flux: Legend Biotech’s Surge, Lilly’s Expansion, and the Shifting Regulatory Landscape on June 4, 2026 rifanmuazin
Posted in Medical Innovations Eli Lilly Doubles Down on Genetic Medicine: A $1.9 Billion Bet on Ascidian’s RNA Exon Editing on June 3, 2026 rifanmuazin
Posted in Digital Health Tools The 340B Stand-Off: Eli Lilly Escalates Data Dispute with Hospitals on June 3, 2026 rifanmuazin
Posted in Medical Innovations The High-Stakes Showdown: Eli Lilly Escalates Battle Over 340B Drug Discount Program on June 2, 2026 rifanmuazin
Posted in Digital Health Tools Escalating Standoff: Eli Lilly Issues Ultimatum to Hospitals Over 340B Drug Pricing on June 2, 2026 rifanmuazin
Posted in Medical Innovations The Great Weight-Loss War: CVS Shifts Strategy to Level the Playing Field for Lilly and Novo Nordisk on May 31, 2026 rifanmuazin
Posted in Digital Health Tools The Triple-Agonist Frontier: Eli Lilly’s Retatrutide Sets a New Benchmark in Obesity Treatment on May 22, 2026 rifanmuazin
Posted in Medical Innovations Eli Lilly’s ‘Triple-G’ Retatrutide Sets New Efficacy Benchmark in Landmark Obesity Trial on May 22, 2026 rifanmuazin
Posted in Digital Health Tools Eli Lilly Strengthens Genetic Medicine Portfolio with Acquisition of Engage Bio on May 21, 2026 rifanmuazin
Posted in Medical Innovations The Next Frontier of Weight Loss: Eli Lilly’s Retatrutide Approaches Surgical Efficacy, But Safety Hurdles Loom on May 21, 2026 rifanmuazin
